Michael Krämer

7k citations
142 papers · 5.6k · 2 hit papers · h-index 39

Impact in

  • Hematology top 0.2%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Blood transfusion and management

Papers in

    • Acute Myeloid Leukemia Research 92
    • Hematopoietic Stem Cell Transplantation 22
    • Drug Transport and Resistance Mechanisms 3
    • Cancer survivorship and care 3

Michael Krämer

139 papers receiving 5.5k citations

Michael Krämer's Hit Papers

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial 2018 · 282 citations
2820+3+7Years since publication100200300

Peers

Michael Krämer
Comparison fields: 5 of 94
  • Hematology 4k
  • Biochemistry 199
  • Oncology 532
  • Health Informatics 55
  • Genetics 149
Replace Mathias Hänel with:
Mathias Hänel Germany
Edward N. Libby United States
Kazuyuki Shimizu Japan
Francis Ayuketang Ayuk Germany
Marc P.E. André Belgium
Hannes Wandt Germany
Mark‐David Levin Netherlands
Michael Pfeilstöcker Austria
Teresa Vallespı́ Spain
Makoto Onizuka Japan
Michael Krämer relative to Mathias Hänel Germany Mathias Hänel's profile →
Citations per field
00.5×2×2.9×
Mathias Hänel · 1×
Citations per year

Countries citing papers authored by Michael Krämer

Since Specialization
Citations

This map shows the geographic impact of Michael Krämer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Krämer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Krämer more than expected).

Fields of papers citing papers by Michael Krämer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Krämer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Krämer. The network helps show where Michael Krämer may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Krämer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Krämer Line = papers co-authored together Michael Krämer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 142 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Hit paper breakdown →
2015350
2 2014299
3
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Hit paper breakdown →
2018282
4 2012261
5 2010254
6 2011217
7 2009177
8 2013175
9 2010154
10 2012119
11 2009115
12 2008114
13 2021112
14 2020100
15 201995
16 201191
17 202184
18 201583
19 201176
20 201576

About Michael Krämer

Michael Krämer is a scholar working on Hematology, Oncology, Pharmacology, Emergency Medicine and Pathology and Forensic Medicine, having authored 142 papers that have together received 5.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (92 papers), Hematopoietic Stem Cell Transplantation (22 papers), Pharmacogenetics and Drug Metabolism (5 papers), Drug Transport and Resistance Mechanisms (3 papers), Cancer survivorship and care (3 papers), Retinoids in leukemia and cellular processes (3 papers), Hematological disorders and diagnostics (3 papers) and Blood transfusion and management (2 papers). The work is most often cited by research in Hematology (4k citations), Biochemistry (199 citations), Oncology (532 citations), Health Informatics (55 citations) and Genetics (149 citations). Michael Krämer has collaborated with scholars based in Germany, United States and Czechia. Frequent co-authors include Gerhard Ehninger, Martin Bornhäuser, Christian Thiede, Christoph Röllig, Markus Andreas Schaich, Malte v. Bonin, Johannes Schetelig, Friedrich Stölzel, Frank Kroschinsky and Uwe Platzbecker. Their work appears in journals such as Blood, Leukemia, Haematologica, Journal of Clinical Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact